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TO THE EDITORTrends in the Use of
Mechanical Circulatory
Support Devices in
Patients Presenting With
ST-Segment Elevation
Myocardial InfarctionCardiogenic shock remains an important cause of
death in acute ST-segment elevation myocardial in-
farction (STEMI) (1). Intra-aortic balloon pump (IABP)
is widely used for hemodynamic support in cardio-
genic shock. The availability of novel mechanical
circulatory support (MCS) devices has increased
the therapeutic armamentarium of a cardiologist. A
recent study from the Nationwide Inpatient Sample
(NIS) demonstrated a signiﬁcant increase in the use of
short-term MCS in the United States during the period
2004 to 2011 (2). However, the study was limited
secondary to inclusion of a heterogeneous popula-
tion, providing little insight into MCS use in the
setting of STEMI. We, therefore, conducted a study to
evaluate the trends and variations in MCS use during
the period 2003 to 2012 in the United States in STEMI
patients complicated by cardiogenic shock.
Data were obtained from the NIS, which contains
discharge-level data fromw8 million hospitalizations
annually from w1,000 hospitals across the United
States. All hospitalizations with the principal diag-
nosis of STEMI, identiﬁed using ICD-9-CM codes,
were considered for inclusion. Of these patients, we
included all patients with an additional diagnosis
of cardiogenic shock (ICD-9: 785.51). The use of
MCS was determined using ICD-9 procedure codes.
These included IABP (ICD-9: 37.61), Impella/Tandem
Heart (ICD-9: 37.68), nonpercutaneous devices (ICD-
9: 37.60, 37.62, 37.65), extracorporeal membrane
oxygenation (ECMO) (ICD-9: 39.65), and percuta-
neous cardiopulmonary support (ICD-9: 39.66). To
evaluate the impact of hospital volume on MCS use,
we divided all hospitals into quartiles based on the
annual volume of primary percutaneous coronary
intervention (PCI) performed. Data from 2003 to 2011were included in this analysis due to a change in pa-
tient sampling strategy and lack of availability of
complete hospital data for participating hospitals in
2012. Multivariable hierarchical logistic regression
analysis was used to account for the clustered nature
of the NIS.
Over a 10-year period (2003 to 2012), 414,367 dis-
charges of STEMI patients were analyzed. Of these
patients, 35,944 patients (8.7%) had a diagnosis code
corresponding to cardiogenic shock. Figure 1A dem-
onstrates the proportion of patients in cardiogenic
shock treated using short-term MCS. We noted a slow
increase in IABP use from 48.6% of cardiogenic shock
cases during 2003 to 57.1% in 2009, followed by a
steady decline in IABP use during recent years (50.6%
in 2012). In contrast, there has been a steep increase
in the use of percutaneous-assist devices and a small
increase in the use of ECMO in cardiogenic shock
cases during the period 2003 to 2012.
Comparison of baseline characteristics between
cardiogenic shock patients treated using MCS support
(n ¼ 16,691) and without MCS support (n ¼ 19,253)
revealed important differences. Patients treated with
MCS were younger (mean age, 64.9 years vs. 69.8
years) and more likely male (67.3% vs. 56.1%)
compared with those not treated with MCS. There
was a lower prevalence of chronic renal failure (11.2%
vs. 14.9%), chronic pulmonary disease (18.7% vs.
21.4%), peripheral vascular disease (7.3% vs. 10.5%),
and hypertension (45.8% vs. 47.0%) among patients
treated with MCS compared with those not treated
with MCS. Importantly, there was a signiﬁcant dif-
ference in the proportion of patients undergoing PCI
on the ﬁrst day of admission between the 2 groups;
62.6% of patients treated with MCS underwent PCI on
the ﬁrst day of admission compared with only 42.9%
of patients not treated with MCS (p < 0.001). As ex-
pected, there was an increase in the proportion of
cardiogenic shock patients treated with PCI on ﬁrst
day of admission from 35.6% in 2003 to 66.0% in 2012
(p trend < 0.001).
There was a signiﬁcant variation in MCS use across
the institutions in the United States. There was
greater use of MCS in cardiogenic shock patients in
urban nonteaching (52.1%) and urban teaching
(56.5%) hospitals compared with rural hospitals
(41.7%, p < 0.001). Similarly, MCS use for cardiogenic
shock was greater in the large-sized hospitals (55.3%)
and medium-sized hospitals (50.5%) compared with
FIGURE 1 MCS Use in ST-Segment Elevation Myocardial Infarction Complicated by
Cardiogenic Shock in the United States
(A) The proportion of ST-segment elevation myocardial infarction patients in cardiogenic
shock treated using various forms ofMCS. The inset shows the use of otherMCSdevices, such
as percutaneous short-term devices (Impella/Tandem Heart), nonpercutaneous devices,
and ECMO, on a magniﬁed scale. (B) The proportion of cardiogenic shock patients treated
usingMCS, after stratiﬁcation of treating hospitals into quartiles based on annual primary PCI
volume. Multivariable hierarchical logistic regression analysis was performed to calculate
the adjusted odds ratios for MCS use after adjusting for demographic characteristics, clinical
characteristics, andhospital characteristics. CI¼ conﬁdence interval; ECMO¼ extracorporeal
membrane oxygenation; IABP ¼ intra-aortic balloon pump; MCS ¼ mechanical circulatory
support; PCI ¼ percutaneous coronary intervention.
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1773small-sized hospitals (45.6%, p < 0.001). On stratiﬁ-
cation of hospitals by geographic location, there
were differences noted in MCS use between the
northeastern (54.4%), midwestern (56.6%), southern
(52.4%), and western (51.8%) United States. Further-
more, on stratiﬁcation of hospitals into quartiles
based on annual primary PCI volume, there was an
increase in MCS use in cardiogenic shock with
increasing primary PCI volume (Figure 1B).
Mortality in patients with cardiogenic shock has
been attributed to hemodynamic deterioration,
multiorgan dysfunction, lack of myocardial salvage,
remote ischemia, and systemic inﬂammatory res-
ponse syndrome (3–6). Although IABP implantation
was initially believed to improve hemodynamics in
cardiogenic shock after STEMI, placement of an IABP
after revascularization in the pivotal IABP-SHOCK II
(Intraaortic Balloon Pump in Cardiogenic Shock II)
trial failed to demonstrate hemodynamic improve-
ment or improvement in clinical endpoints (6). Our
study has evaluated the trend in MCS use in high-risk
STEMI patients with cardiogenic shock from a non-
trial, contemporary real-world setting. We noted an
increase in the IABP use for cardiogenic shock during
the period 2003 to 2009, followed by a decline during
the period 2010 to 2012. This was partially compen-
sated for by an increase in the use of devices such
as the Impella and Tandem Heart. This might be
attributable to the ease of implantation, decreasing
conﬁdence in the IABP, and the need for added he-
modynamic support. A signiﬁcant proportion of pa-
tients treated using other MCS devices underwent
IABP implantation concomitantly (47.7%), implying
inadequate support with IABP in patients with
intractable cardiogenic shock.
An important ﬁnding was heterogeneity of MCS
use across various institutions. The variation may be
explained partly by differences in case mix or hospital
characteristics. Hospital size may be an indirect
marker of available health care resources, and large-
sized hospitals might have access to more resources
for patient management. It is also plausible that low-
volume centers are more selective in treating patients
with STEMI and cardiogenic shock. We noted an
interesting association between the annual primary
PCI volume and MCS use in U.S. hospitals. This
considerable in-hospital variation clearly indicates
the lack of guidelines for MCS use during most of the
study period. The guidelines for MCS use have
recently been published and would potentially serve
to reduce some of these discrepancies (7).
Our study has several limitations. First, NIS is an
administrative database, which may be subject to
errors in coding of diseases or procedures.Cardiogenic shock was identiﬁed using the ICD-9
code reported by the treating hospital and thus may
not be uniform across participating institutions. Un-
like the IABP-SHOCK II trial, which included all acute
myocardial infarction patients, our study was res-
tricted to patients with STEMI. Identiﬁcation of pa-
tients with non-STEMI in an administrative dataset
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1774such as NIS would likely identify a heterogeneous
group of patients with multiple different causes for
cardiac biomarker elevation. In an administrative
dataset, we could probably be most certain of deﬁn-
itive diagnoses such as STEMI; hence, we decided to
restrict our analysis to this cohort. In addition,
inclusion of non-STEMI patients (with much lower
rates of cardiogenic shock) was a criticism of the
IABP-SHOCK II trial. Second, because the unit of
analysis in the NIS database is “unique admission”
rather than “unique patient,” it is possible that a
patient might have been represented more than once
in case of repeat admission for recurrent STEMI.
Third, this is a retrospective observational study,
which may be subject to traditional biases of obser-
vational studies. However, these limitations might be
partially compensated for by the large size of the NIS
database and a uniform representation of all regions
of the United States.
In conclusion, there was a steady increase in the
use of IABP for cardiogenic shock during the period
2003 to 2009, followed by a slow decline in its use
during the period 2010 to 2012. This was partially
compensated for by a steep increase in the use of
short-term percutaneous MCS during recent years.
There was signiﬁcant variability in MCS use among
STEMI patients with cardiogenic shock, based on the
annual PCI volume of the treating hospital. Increase in
annual PCI volume was correlated with an increase in
MCS use in STEMI patients complicated by cardio-
genic shock.
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